In a Process Instrumentation article, How to ensure reliable pressure transmitter measurement in pharmaceutical applications, Emerson’s Brandon Haschke shares how “Advanced hygienic pressure transmitters can reduce downtime and operating costs thanks to long-term stability that requires fewer calibrations.”
Emerson’s Christian Berg presented Are We There Yet? Tackling Manufacturing Challenges with the Digital Plant at the Pharma Manufacturing World Summit in Boston.
The rapid development of the COVID-19 vaccine has created a dramatic shift in the way the public and life sciences organizations view the manufacturing of pharmaceuticals. In a recent Q&A with Pharma Manufacturing, Nathan Pettus, president of Emerson’s process...
The BioPhorum Operations Group (BPOG) established a digital plant maturity model (DPMM) for biopharmaceutical manufacturing to define stages of factory evolution “from simple paper-based plants through to the fully automated and integrated ‘adaptive plant’ of the future.” The model gives organizations a common tool for industry comparison and measurement of progress. It also provides a platform to facilitate collaboration within the life sciences industry and its technology providers.
It isn’t news that the global pandemic upended the way we operate our plants. When social distancing trapped our most valuable personnel outside the facilities we rely on, it suddenly meant finding new ways to get critical work done. But the reality is, those changes...
We have witnessed an incredible change the last few years in how life sciences manufacturers deliver treatments. Today’s focus is on fast results, and that means products patients rely on cannot sit on shelves for weeks or months waiting on quality validation. In a...
In a Plastic News article, Automation suppliers help meet demand for COVID-19 testing kits, Emerson’s Vernon Murray highlights the importance of welding technology in driving production efficiency.
There is a new requirement for medical device companies selling into the European market, called the Medical Device Regulation, or MDR. This new regulation places a focus on the supply chain, meaning suppliers in the industry must have a good understanding of the new...
In an Australasian BioTechnology article, Facilities for a Strong Future, Emerson’s Michalle Adkins and Makarand Mujumdar share how pharmaceutical and biotech manufacturers can improve local capacity to meet the needs of the regions in which they operate.
There are four core pillars we look to address in order to support pharmaceutical and biopharmaceutical manufacturers in achieving line and facility efficiency goals.
Reliability of assets used in the manufacturing process is paramount for safe, efficient and effective operations. Unplanned asset failures, improper asset performance, poor maintenance planning, and untimely follow-through can cause shutdowns, under-utilized production equipment, deviations, or material/product losses.
Initiating Good Manufacturing Practices (GMP) production operations, whether as part of facility start-up, product changeover, or following a shutdown, requires complex coordination of both logical and physical process controls. Inefficient configuration and qualification practices for automation and information management systems can lead to both start-up delays and productivity losses.
We invite you to follow us on Facebook, LinkedIn, Twitter and YouTube to keep up to date on all the latest news, events and innovations to help you take on and solve your toughest challenges.
Please do, Just link back to the post and send us a quick note so we can share your work. Thanks!
Our Global Community
The opinions expressed here are the personal opinions of the authors. Content published here is not read or approved by Emerson before it is posted and does not necessarily represent the views and opinions of Emerson.